- Home
- GRAN vs MGNX Comparison
GRAN vs MGNX Comparison
Compare GRAN & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRAN
- MGNX
- Stock Information
- Founded
- GRAN 2020
- MGNX 2000
- Country
- GRAN Hong Kong
- MGNX United States
- Employees
- GRAN N/A
- MGNX N/A
- Industry
- GRAN
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- GRAN
- MGNX Health Care
- Exchange
- GRAN NYSE
- MGNX Nasdaq
- Market Cap
- GRAN 129.3M
- MGNX 114.2M
- IPO Year
- GRAN 2025
- MGNX 2013
- Fundamental
- Price
- GRAN $5.41
- MGNX $1.71
- Analyst Decision
- GRAN
- MGNX Hold
- Analyst Count
- GRAN 0
- MGNX 9
- Target Price
- GRAN N/A
- MGNX $5.33
- AVG Volume (30 Days)
- GRAN 396.4K
- MGNX 1.2M
- Earning Date
- GRAN 01-01-0001
- MGNX 08-05-2025
- Dividend Yield
- GRAN N/A
- MGNX N/A
- EPS Growth
- GRAN N/A
- MGNX N/A
- EPS
- GRAN 0.25
- MGNX N/A
- Revenue
- GRAN $4,731,044.00
- MGNX $154,050,000.00
- Revenue This Year
- GRAN N/A
- MGNX N/A
- Revenue Next Year
- GRAN N/A
- MGNX N/A
- P/E Ratio
- GRAN $19.39
- MGNX N/A
- Revenue Growth
- GRAN 17.00
- MGNX 255.31
- 52 Week Low
- GRAN $4.30
- MGNX $0.99
- 52 Week High
- GRAN $6.70
- MGNX $5.77
- Technical
- Relative Strength Index (RSI)
- GRAN N/A
- MGNX 59.62
- Support Level
- GRAN N/A
- MGNX $1.47
- Resistance Level
- GRAN N/A
- MGNX $1.88
- Average True Range (ATR)
- GRAN 0.00
- MGNX 0.12
- MACD
- GRAN 0.00
- MGNX 0.03
- Stochastic Oscillator
- GRAN 0.00
- MGNX 68.81
About GRAN GRANDE GROUP LIMITED
Grande Group Ltd is a financial service providers in Hong Kong. It is a financial firm that focuses on providing quality corporate finance advisory services to clients. The company in engage in Type 1 (dealing in securities) and Type 6 (advising on corporate finance) regulated activities in Hong Kong.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.